SGLT2i in AS
Research type
Research Study
Full title
The role of Sodium Glucose Cotransporter 2 inhibitors in the management of patients with aortic stenosis
IRAS ID
328005
Contact name
Vassilios Vassiliou
Contact email
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 6 months, 1 days
Research summary
The aortic valve is one of the heart valves that controls the blood flow from the heart to the rest of the body. In some people, there can be “wear and tear” of the valve resulting in significant narrowing of the valve with time (termed aortic stenosis). As a result, the heart must work much harder to pump enough blood, through the restricted valve, to the body efficiently. This continuously increased workload on the heart muscle can result in thickening or scarring of the heart muscle. There is currently no medicine to protect the heart muscle, but we want to study a medication called empagliflozin, which is a Sodium Glucose Cotransporter 2 inhibitor (SGLT2i) to see if it protects the heart muscle of patients with aortic stenosis. SGLT2i are already used to treat heart problems such as heart failure, and they have positive effects on the heart muscle.
Therefore, the aim of this study is to investigate whether the use of empagliflozin prevents the formation of scar or the abnormal thickening of the heart muscle in patients with aortic stenosis. Using blood tests, advanced imaging techniques that do not involve radiation or cause any harm (such as echocardiography and cardiovascular magnetic resonance), we intend to study their effect on the heart muscle of these patients. For this purpose, we aim to randomly assign patients to either take empagliflozin or not take it, and test their heart function and quality of life (through blood tests, scans and validated questionnaires) at baseline and after 6 months. We want to see if the medication can improve how the heart muscle works, and if it helps to preserve the overall function of the heart.REC name
South East Scotland REC 01
REC reference
24/SS/0004
Date of REC Opinion
22 Jan 2024
REC opinion
Further Information Favourable Opinion